NASDAQ: EQEquillium Inc Stock
$0.59-0.02 (-3.28%)
Updated Dec 7, 2023
EQ Price
$0.59
Fair Value Price
$1.30
Market Cap
$20.72M
52 Week Low
$0.45
52 Week High
$1.51
P/E
-2.68x
P/B
0.86x
P/S
0.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$42.63M
Earnings
-$8.22M
Gross Margin
100%
Operating Margin
-16.17%
Profit Margin
-19.3%
Debt to Equity
1.29
Operating Cash Flow
$12M
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EQ Overview
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EQ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EQ ($0.59) is undervalued by 54.69% relative to our estimate of its Fair Value price of $1.30 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EQ ($0.59) is significantly undervalued by 54.69% relative to our estimate of its Fair Value price of $1.30 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EQ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EQ due diligence checks available for Premium users.
Be the first to know about important EQ news, forecast changes, insider trades & much more!
EQ News
Valuation
EQ fair value
Fair Value of EQ stock based on Discounted Cash Flow (DCF)
Price
$0.59
Fair Value
$1.30
Undervalued by
54.69%
EQ ($0.59) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EQ ($0.59) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EQ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EQ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.68x
Industry
11.53x
Market
31.17x
EQ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
5.45x
EQ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EQ's financial health
Profit margin
Revenue
$8.9M
Net Income
-$3.7M
Profit Margin
-41.8%
EQ's Earnings (EBIT) of -$6.89M... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$55.2M
Liabilities
$31.1M
Debt to equity
1.29
EQ's short-term assets ($53.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EQ's short-term assets ($53.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EQ's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EQ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$11.0M
Financing
-$260.0k
EQ's operating cash flow ($11.61M)... subscribe to Premium to read more.
Debt Coverage Financials
EQ vs Biotech Stocks
Equillium Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.